OTTAWA, Sept. 16, 2014 /CNW/ - The Canadian Dermatology Association's
(CDA) mission is to promote the highest quality standards for
dermatologic care in Canada and have issued a position statement on the
Herpes Zoster vaccine.
Herpes zoster, or shingles, results from reactivation of the
varicella-zoster virus, which lies dormant in the spinal and cranial
sensory ganglia following a primary infection with varicella
(chickenpox), usually during childhood. The most frequent complication
is post-herpetic neuralgia (PHN), which typically has a major adverse
impact on quality of life, especially in elderly persons.
A vaccine that may limit the occurrence of herpes zoster is currently
available in Canada. It is a live, mercury-free, attenuated vaccine
that is indicated for the prevention of herpes zoster in adults over
the age of 50 years. In the pivotal efficacy trial, the vaccine reduced
the incidence of Herpes Zoster by 51.3% in the study population of
38,546 adults greater than 60 years of age.
The Canadian Dermatology Association recommends discussing with your
primary physician or your dermatologist whether the Herpes Zoster
vaccine is right for you. The CDA's position statement on the Herpes
Zoster vaccine can be downloaded at dermatology.ca.
The Canadian Dermatology Association, founded in 1925, represents
Canadian dermatologists. The association provides easy access to the
largest, most reliable source of medical knowledge on dermatology. CDA
exists to advance the science and art of medicine and surgery related
to the care of the skin, hair and nails; provide continuing
professional development for its members; support and advance patient
care; provide public education on sun protection and other aspects of
skin health; and promote a lifetime of healthier skin, hair and nails.
By doing so, CDA informs and empowers both medical professionals and
the Canadian public.
SOURCE: Canadian Dermatology Association
For further information:
Jennifer Scott, Director of Communications
Office: 613.738.1748 | 1.800.267.3376 Ext. 222